Screening for sensory deficits in childhood cancer survivors
Highlighting Patients At Risk for Sensory Screening (HPARSS) to Enhance Sensory Deficit Screening in Childhood Cancer Survivors
This study is trying to find a better way to check for sensory problems in childhood cancer survivors by using their treatment history to identify who needs testing.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 146 (estimated) |
| Ages | 7 Years to 17 Years |
| Sex | All |
| Sponsor | Washington University School of Medicine Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (St Louis, Missouri) |
| Trial ID | NCT05582551 on ClinicalTrials.gov |
What this trial studies
This study aims to improve the screening process for sensory deficits in childhood cancer survivors by identifying patients at risk based on their treatment history. Collaborators at Washington University School of Medicine will create a document called HPARSS that links therapy-related risks to specific screening procedures. This document will prompt primary oncology providers to implement necessary screenings and diagnostic tests for these patients. The study utilizes a cross-sectional design to address organizational barriers in timely screening.
Who should consider this trial
Good fit: Ideal candidates are childhood cancer survivors aged 7 to 17 who completed their cancer treatment 6 months to 2 years prior and are followed at the Washington University School of Medicine.
Not a fit: Patients currently undergoing active cancer treatment or those already receiving care for sensory deficits may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection and management of sensory deficits in childhood cancer survivors, improving their quality of life.
How similar studies have performed: Other studies have shown success in implementing screening protocols for childhood cancer survivors, indicating that this approach has potential.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with a diagnosis of pediatric cancer (diagnosis at \<18 years of age) * Treatment including chemotherapy and/or radiation therapy * Completion of all cancer therapy for at least 6 months and less than 2 years * Followed in the Division of Pediatric Hematology/Oncology Program at the Washington University School of Medicine * Current age between 7 and 17 years of age (age where all of the screening tests are both valid and have been successfully performed by our group) * English speaking Exclusion Criteria: * Undergoing active cancer treatment * Patient under the care of the Late Effects Program at St. Louis Children's Hospital * Received previous diagnostic testing or rehabilitative therapy for a secondary deficit eligible for screening. * Parents and/or patient illiteracy * No contact with treatment team in the past two years * In foster care or without a legal guardian
Where this trial is running
St Louis, Missouri
- St. Louis Children's Hospital - Washington University School of Medicine — St Louis, Missouri, United States (Recruiting)
Study contacts
- Principal investigator: Robert J Hayashi, M.D. — Washington University School of Medicine
- Study coordinator: Robert J Hayashi, M.D.
- Email: hayashi_r@wustl.edu
- Phone: 314-454-6018
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.